Cyclo Therapeutics, Inc. (CYTH)
0.7206
0.00 (0.00%)
Inactive · Last trade price on Mar 26, 2025
Cyclo Therapeutics Revenue
Cyclo Therapeutics had revenue of $233.77K in the quarter ending September 30, 2024, a decrease of -52.82%. This brings the company's revenue in the last twelve months to $870.73K, down -8.52% year-over-year. In the year 2023, Cyclo Therapeutics had annual revenue of $1.08M, down -21.76%.
Revenue (ttm)
$870.73K
Revenue Growth
-8.52%
P/S Ratio
22.38
Revenue / Employee
$108,841
Employees
8
Market Cap
20.73M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 1.08M | -299.36K | -21.76% |
| Dec 31, 2022 | 1.38M | -210.00K | -13.24% |
| Dec 31, 2021 | 1.59M | 682.38K | 75.54% |
| Dec 31, 2020 | 903.38K | -103.82K | -10.31% |
| Dec 31, 2019 | 1.01M | -4.28K | -0.42% |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2014 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionCYTH News
- 9 months ago - CYCLO THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Cyclo Therapeutics, Inc. - CYTH - Business Wire
- 10 months ago - Cyclo Therapeutics Presents Positive Preliminary Data from Ongoing Phase 3 TransportNPC™ Open-Label Sub-Study in Patients (< 3 Years Old) - Business Wire
- 11 months ago - Cyclo Therapeutics to Present at the 21st Annual WORLDSymposium™ 2025 - Business Wire
- 11 months ago - SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LTRPA, LTRPB, CYTH, SKGR on Behalf of Shareholders - PRNewsWire
- 1 year ago - Niemann-Pick Disease Pipeline Market Research 2024: Comprehensive Insights about 12+ Drugs Featuring Cyclo Therapeutics, Azafaros, IntraBio - GlobeNewsWire
- 1 year ago - Cyclo Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update - Business Wire
- 1 year ago - Cyclo Therapeutics Presents Encouraging Preliminary Safety Data from Ongoing Pivotal Phase 3 Study and Substudy for the Treatment of Niemann-Pick Disease Type C1 (NPC1) - Business Wire
- 1 year ago - Accession Risk Management Group Closes $1 Billion Financing to Further Accelerate Growth of Risk Strategies and One80 Intermediaries - Business Wire